Encapsulating peritoneal sclerosis: A rare, serious but potentially curable complication of peritoneal dialysis-experience of a referral centre in Germany

Nephrology Dialysis Transplantation

Volumn 28, Issue 4, 2013, Pages 1021-1030

  Latus, Joerg ^a   Ulmer, Christoph ^a   Fritz, Peter ^a   Rettenmaier, Bianka ^a   Biegger, Dagmar ^b   Lang, Thomas ^b   Ott, German ^a   Scharpf, Christoph ^a   Kimmel, Martin ^a   Steurer, Wolfgang ^a   Alscher, M Dominik ^a   Braun, Niko ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

encapsulating peritoneal sclerosis; histopathological findings; long term outcome

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; TAMOXIFEN;

ABDOMINAL PAIN; ABDOMINAL SURGERY; ADHESIOLYSIS; ADULT; APPENDECTOMY; ARTICLE; ASCITES; BODY MASS; CALCIFICATION; CAUSE OF DEATH; CHOLECYSTECTOMY; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GERMANY; HEMICOLECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTESTINE DISTENSION; INTESTINE FISTULA; INTESTINE OBSTRUCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MALE; NAUSEA AND VOMITING; ONSET AGE; OUTCOME ASSESSMENT; PARENTERAL NUTRITION; PERITONEAL BIOPSY; PERITONEAL DISEASE; PERITONEAL FIBROSIS; PERITONEAL THICKENING; PERITONECTOMY AND ENTEROLYSIS; PERITONEUM ADHESION; PERITONITIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RARE DISEASE; RECURRENT DISEASE; REOPERATION; RETROSPECTIVE STUDY; SEPSIS; SMALL INTESTINE RESECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; SURGICAL MORTALITY; SURVIVAL; TREATMENT OUTCOME; VOMITING; WEAKNESS; WEIGHT REDUCTION;

FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PROGNOSIS; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84876008716     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs159     Document Type: Article

References (52)

1. Kawaguchi Y, Kawanishi H, Mujais S et al. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000; 20 (Suppl 4): S43-S55.
2. Brown MC, Simpson K, Kerssens JJ et al. Encapsulating peritoneal sclerosis in the new millennium: a national cohort study. Clin J Am Soc Nephrol 2009; 4: 1222-1229.
3. Johnson DW, Cho Y, Livingston BE et al. Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. Kidney Int 2010; 77: 904-912.
4. Oules R, Challah S, Brunner FP. Case-control study to determine the cause of sclerosing peritoneal disease. Nephrol Dial Transplant 1988; 3: 66-69.
5. Nakamoto H. Encapsulating peritoneal sclerosis-a clinician's approach to diagnosis and medical treatment. Perit Dial Int 2005; 25(Suppl 4): S30-S38. (Pubitemid 41600357)
6. Kawanishi H, Kawaguchi Y, Fukui H et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis 2004; 44: 729-737. (Pubitemid 39237618)
7. Rigby RJ, Hawley CM. Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant 1998; 13: 154-159. (Pubitemid 28033596)
8. Nomoto Y, Kawaguchi Y, Kubo H et al. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis 1996; 28: 420-427. (Pubitemid 26304423)
9. Summers AM, Clancy MJ, Syed F et al. Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int 2005; 68: 2381-2388. (Pubitemid 43117819)
10. Fieren MW, Betjes MG, Korte MR et al. Posttransplant encapsulating peritoneal sclerosis: a worrying new trend? Perit Dial Int 2007; 27: 619-624. (Pubitemid 351843476)
11. Summers AM, Abrahams AC, Alscher MD et al. A collaborative approach to understanding EPS: the European perspective. Perit Dial Int 2011; 31: 245-248.
12. Kawanishi H, Moriishi M, Tsuchiya S. Experience of 100 surgical cases of encapsulating peritoneal sclerosis: investigation of recurrent cases after surgery. Adv Perit Dial 2006; 22: 60-64.
13. Kawanishi H, Moriishi M, Ide K et al. Recommendation of the surgical option for treatment of encapsulating peritoneal sclerosis. Perit Dial Int 2008; 28(Suppl 3): S205-S210.
14. Braun N, Fritz P, Biegger D et al. Difference in the expression of hormone receptors and fibrotic markers in the human peritoneum-implications for therapeutic targets to prevent encapsulating peritoneal sclerosis. Perit Dial Int 2011; 31: 291-300.
15. Vlijm A, Stoker J, Bipat S et al. Computed tomographic findings characteristic for encapsulating peritoneal sclerosis: a case-control study. Perit Dial Int 2009; 29: 517-522.
16. Braun N, Alscher MD, Kimmel M et al. Encapsulating peritoneal sclerosis-an overview. Nephrol Ther 2011; 7: 162-171.
17. Honda K, Nitta K, Horita S et al. Histologic criteria for diagnosing encapsulating peritoneal sclerosis in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 2003; 19: 169-175.
18. Balasubramaniam G, Brown EA, Davenport A et al. The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2009; 24: 3209-3215.
19. Guest S. Hypothesis: gender and encapsulating peritoneal sclerosis. Perit Dial Int 2009; 29: 489-491.
20. Lee HY, Kim BS, Choi HY et al. Sclerosing encapsulating peritonitis as a complication of long-term continuous ambulatory peritoneal dialysis in Korea. Nephrology (Carlton) 2003; 8(Suppl): S33-S39. (Pubitemid 38056412)
21. Kawanishi H. Encapsulating peritoneal sclerosis in Japan: prospective multicenter controlled study. Perit Dial Int 2001; 21 (Suppl 3): S67-S71. (Pubitemid 34406780)
22. Cano A, Perez-Moreno MA, Rodrigo I et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2: 76-83.
23. Del Peso G, Jimenez-Heffernan JA, Bajo MA et al. Epithelial-tomesenchymal transition of mesothelial cells is an early event during peritoneal dialysis and is associated with high peritoneal transport. Kidney Int Suppl 2008; 108: S26-S33. (Pubitemid 351466514)
24. Kawanishi H, Watanabe H, Moriishi M et al. Successful surgical management of encapsulating peritoneal sclerosis. Perit Dial Int 2005; 25(Suppl 4): S39-S47. (Pubitemid 41600358)
25. Honda K, Oda H. Pathology of encapsulating peritoneal sclerosis. Perit Dial Int 2005; 25(Suppl 4): S19-S29. (Pubitemid 41600356)
26. Lambie ML, John B, Mushahar L et al. The peritoneal osmotic conductance is low well before the diagnosis of encapsulating peritoneal sclerosis is made. Kidney Int 2010; 78: 611-618.
27. Korte MR, Sampimon DE, Lingsma HF et al. Risk factors associated with encapsulating peritoneal sclerosis in Dutch EPS study. Perit Dial Int 2011; 31: 269-278.
28. Slingeneyer A. Preliminary report on a cooperative international study on sclerosing encapsulating peritonitis. Contrib Nephrol 1987; 57: 239-247.
29. Martikainen TA, Teppo AM, Gronhagen-Riska C et al. Glucosefree dialysis solutions: inductors of inflammation or preservers of peritoneal membrane? Perit Dial Int 2005; 25: 453-60. (Pubitemid 41448400)
30. Posthuma N, Verbrugh HA, Donker AJ et al. Peritoneal kinetics and mesothelial markers in CCPD using icodextrin for daytime dwell for two years. Perit Dial Int 2000; 20: 174-180.
31. Moriishi M, Kawanishi H. Fibrin degradation products are a useful marker for the risk of encapsulating peritoneal sclerosis. Adv Perit Dial 2008; 24: 56-59.
32. Davies SJ, Woodrow G, Donovan K et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003; 14: 2338-2344. (Pubitemid 37052381)
33. Parikova A, Zweers MM, Struijk DG et al. Peritoneal effluent markers of inflammation in patients treated with icodextrinbased and glucose-based dialysis solutions. Adv Perit Dial 2003; 19: 186-190.
34. Duman S, Sen S. Technical aspects in studying peritoneal morphology in animal models of peritoneal dialysis. Perit Dial Int 2009; 29(Suppl 2): S40-S44.
35. Sherif AM, Yoshida H, Maruyama Y et al. Comparison between the pathology of encapsulating sclerosis and simple sclerosis of the peritoneal membrane in chronic peritoneal dialysis. Ther Apher Dial 2008; 12: 33-41. (Pubitemid 351197450)
36. Honda K, Nitta K, Horita S et al. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 1996; 72: 171-176. (Pubitemid 26035372)
37. Williams JD, Craig KJ, Topley N et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-479. (Pubitemid 34106290)
38. Margetts PJ, Bonniaud P, Liu L et al. Transient overexpression of TGF-{beta}1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 2005; 16: 425-436. (Pubitemid 41725138)
39. Braun N, Alscher DM, Fritz P et al. Podoplanin-positive cells are a hallmark of encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2011; 26: 1033-1041.
40. von Ruhland CJ, Newman GR, Topley N et al. Can artifact mimic the pathology of the peritoneal mesothelium? Perit Dial Int 2003; 23: 428-433. (Pubitemid 37321745)
41. Tarzi RM, Lim A, Moser S et al. Assessing the validity of an abdominal CT scoring system in the diagnosis of encapsulating peritoneal sclerosis. Clin J Am Soc Nephrol 2008; 3: 1702-1710.
42. Brown EA, Van Biesen W, Finkelstein FO et al. Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: position paper for ISPD. Perit Dial Int 2009; 29: 595-600.
43. Kawanishi H, Moriishi M. Epidemiology of encapsulating peritoneal sclerosis in Japan. Perit Dial Int 2005; 25(Suppl 4): S14-S18. (Pubitemid 41600355)
44. Bhandari S. Recovery of gastrointestinal function after renal transplantation in patients with sclerosing peritonitis secondary to continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1996; 27: 604.
45. Genereau T, Bellin MF, Wechsler B et al. Demonstration of efficacy of combining corticosteroids and colchicine in two patients with idiopathic sclerosing mesenteritis. Dig Dis Sci 1996; 41: 684-688. (Pubitemid 26140074)
46. Mori Y, Matsuo S, Sutoh H et al. A case of a dialysis patient with sclerosing peritonitis successfully treated with corticosteroid therapy alone. Am J Kidney Dis 1997; 30: 275-278. (Pubitemid 27330346)
47. Afthentopoulos IE, Passadakis P, Oreopoulos DG et al. Sclerosing peritonitis in continuous ambulatory peritoneal dialysis patients: one center's experience and review of the literature. Adv Ren Replace Ther 1998; 5: 157-167. (Pubitemid 28323575)
48. Bozkurt D, Sipahi S, Cetin P et al. Does immunosuppressive treatment ameliorate morphology changes in encapsulating peritoneal sclerosis? Perit Dial Int 2009; 29(Suppl 2): S206-S210.
49. Maruyama Y, Nakayama M. Encapsulating peritoneal sclerosis in Japan. Perit Dial Int 2008; 28(Suppl 3): S201-S204.
50. Kawanishi H, Harada Y, Noriyuki T et al. Treatment options for encapsulating peritoneal sclerosis based on progressive stage. Adv Perit Dial 2001; 17: 200-204.
51. Kawanishi H, Shintaku S, Moriishi M et al. Seventeen years' experience of surgical options for encapsulating peritoneal sclerosis. Adv Perit Dial 2011; 27: 53-58.
52. Yeates K, Zhu N, Vonesh E et al. Hemodialysis and peritoneal dialysis are associated with similar outcomes for end-stage renal disease treatment in Canada. Nephrol Dial Transplant 2012; 13 (Epub ahead of print).